Preparation of *C***2-Symmetric Bis[2-(diphenylphosphino)ferrocen-1-yl] methane and Its Use in Rhodium- and Ruthenium-Catalyzed Hydrogenation**

by Yaping Wang^a), Walter Weissensteiner^{*a}), Kurt Mereiter^b), and Felix Spindler^{*c})

a) Institute of Organic Chemistry, University of Vienna, Währinger Straße 38, A-1090 Vienna b) Institute of Chemical Technologies and Analytics, Vienna University of Technology, Getreidemarkt 9, A-1060 Vienna c) *Solvias AG*, WKL 127, P. O. Box, CH-4002 Basel

Dedicated to Professor *Giambattista Consiglio* on the occasion of his 65th birthday

The two diphosphine ligands (R_p, R_p) - and (S_p, S_p) -bis[2-(diphenylphospino)ferrocenyl]methane, (R_p, R_p) - and (S_p, S_p) -1, resp., were prepared in six steps from (*S*)- and (*R*)-ferrocenyl tolyl sulfoxide, respectively (*Scheme*). In the solid state, both the diborane complex (R_p, R_p) -1· (BH₃)₂ and the palladium dichloride complex $[PolCl₂(R_p, R_p)$ -1)] were found to adopt $C₂$ -pseudosymmetric structures according to X-ray analyses (*Figs. 2* and *3*). In the Rh- and Ru-catalyzed hydrogenation of selected alkenes and ketones in the presence of the new ligands, enantioselectivities of up to 55% ee were obtained.

1. Introduction. – Homogeneous enantioselective hydrogenation has now developed into a mature synthetic methodology, not only for scientific purposes [1], but also for the production of enantiomerically pure bioactive ingredients and fine chemicals on an industrial scale [2]. Rhodium (Rh) and ruthenium (Ru) complexes of diphosphine ligands are preferentially used for the enantioselective hydrogenation of alkenes and ketones [3]. However, of the innumerable chiral diphosphines that have been investigated, only a few have proven suitable for industrial processes. These include C_2 -symmetric ligands like Dipamp [4], Binap [5], or Duphos [6], as well as *C*1-symmetric Josiphos [7] ligands. However, despite the huge number of diphosphines that have been tested, particularly in terms of additional industrial applications, ligand development continues intensively.

For a long time, especially since the early development of Diop [8] and Dipamp, ligand design has focused primarily on bidentate and C_2 -symmetric diphosphines, which were considered superior to mono- or bidentate C_1 -symmetric ligands. This view has changed significantly, especially since *C*1-symmetric Josiphos-type derivatives were successfully used as catalyst ligands in industrial hydrogenation processes [7]. Nowadays, complexes of certain monodentate ligands are also known to catalyze hydrogenations with excellent enantioselectivity [9]. In recent years, the successful application of Josiphos-type ligands in enantioselective hydrogenations and other reactions has boosted the further development of C_1 - and, to a much lesser extent, of C_2 symmetric ferrocenyl-based diphosphines [10]. In addition, our search for novel classes of ferrocenyl diphosphines has mainly focused on C_1 -symmetric ligands with either a homo- or a heteroannulene-bridged ferrocene backbone [11], *e.g.*, Bifep-type biferro-

^{© 2006} Verlag Helvetica Chimica Acta AG, Zürich

cenes [12], or derivatives having a ferrocenyl-aryl backbone. Development of the latter system eventually resulted in the Walphos-type ligand family [13].

Recently, in the search for new backbones, we envisaged that ligand development could be extended to additional *C*₂-symmetric ferrocenyl diphosphines, and we herein report the preparation and structural analysis of (R_p, R_p) - and (S_p, S_p) -bis[2-(diphenylphospino)ferrocen-1-yl)methane (**1**) and discuss the application of these compounds in enantioselective hydrogenation reactions.

2. Results and Discussion. -2.1 . *Synthesis*. In general, chiral C_2 -symmetric ferrocene derivatives can be obtained either by hetero-substitution of the ferrocene backbone or by appropriately linking two homochiral *C*1-symmetric ferrocene units. Examples of the former system include 1,1'-disubstituted P-stereogenic ferrocenes of type **A** (*Fig. 1*) [14] and Ferriphos-type ligands [15]. The latter type of compounds is represented by Bifep [16], Trap [17], the cyclohexyldiamide-linked bisferrocenyl derivative **B** [18], and the newly synthesized ligand **1** (see *Scheme* below).

Fig. 1. *Examples of* C*2-symmetric ferrocenyl diphosphine ligands*

Attempts to build up the diferrocenylmethane backbone in one step from *ortho*lithiated ferrocenyl tolyl sulfoxide (2-Li-**2**) and ethyl formate failed. A similar observation was recently reported in the literature [19]. As a result, we decided to synthesize the ligand backbone in a stepwise fashion by adopting *Kagan*'s sulfoxide methodology (*Scheme*) [20]. First, 2-lithio-tributylstannylferrocene $((R_p)$ -3) was prepared by reacting (S_c, R_p) -4, easily accessible from 4-tolylsulfinylferrocene $((S_c)$ -2), with *t*-BuLi [21]. Trapping of (R_p) -3 with DMF as the electrophile gave the corresponding aldehyde (R_p) -5. In the subsequent step, reaction of (R_p) -5 with (R_p) -3 led to the intermediate (R_p, R_p) -6 in which the final ligand backbone is already preformed. It should be noted that, although Scheme. *Preparation of the New Ligand* (R_p, R_p) -1 *and Its Complex* $[PdCl_2((R_p, R_p)$ *-1)]*

an alternative preparation of aldehyde **5** has been reported previously [22], in our particular case the synthesis of **5** from **4** is more suitable, given that, in this route, both precursors of **6** (*i.e.*, **3** and **5**) are accessible from a single common intermediate. Reduction of (R_p, R_p) -6 with BH₃ in THF [23] gave the bis(tributylstannyl) derivative (R_p, R_p) -7, which was reacted with *t*-BuLi and chloro(diphenyl)phosphine, and subsequently trapped with BH₃ in THF to afford the diborane complex (R_p, R_p) -1· (BH₃)₂. Finally, deprotection with Et₂NH led to the target C_2 -symmetric diphosphine ligand (R_p, R_p) -1. To study the coordination behavior of ligand **1**, its palladium dichloride complex $[PdCl_2((R_p, R_p)-1)]$ was prepared by reacting $(R_p, R_p)-1$ with $[PdCl_2(MeCN)_2]$.

2.2. *Structure Elucidation*. The structural integrity of all compounds was assessed by NMR spectroscopy and, in the cases of (R_p, R_p) -1· $(BH_3)_2$ and $[PdCl_2((R_p, R_p)$ -1)], also by single-crystal X-ray-diffraction analyses. Views of the molecular structures are shown in *Figs.* 2 and 3 for (R_p, R_p) -1 \cdot (BH₃)₂ and [PdCl₂((R_p, R_p) -1)], respectively. The NMR results show that, in solution, both ligand 1 and its complex $[\text{PdCl}_2((R_p, R_p)-1)]$ show twofold symmetry. However, in the solid state, they are found in asymmetric environments, but show clear *C*₂-pseudosymmetry.

The molecular structure of $[\text{PdCl}_2((R_n, R_n)-1)]$ is of particular interest. Both ferrocene units are arranged in a propeller-like fashion that places the Pd-atom and the

Fig. 2. *X-Ray crystal structure of* (R_p, R_p) -1·*(BH₃)*₂. Ellipsoids are shown at the 40% level; H-atoms have been omitted for clarity. Selected distances [Å] and angles [°]: (Fe-C_{Cp)aver}, 2.046(1); P(1)- $C(2)$, 1.798(1); $P(1) - C(22)$, 1.816(1); $P(1) - C(28)$, 1.818(1); $P(1) - B(1)$, 1.929(1); $P(2) - C(12)$, 1.800(1); P(2)-C(34), 1.820(1); P(2)-B(2), 1.939(1); C(21)-C(1), 1.510(2); C(21)-C(11), 1.512(2); $C(1) - C(21) - C(11)$, 112.0(1); B(1)-P(1)-C(2)-C(1), 42.8(1); B(2)-P(2)-C(12)-C(11), 43.2(1); $P(1)-C(2)-C(1)-C(21), 1.1(2); P(2)-C(12)-C(11)-C(21), 2.5(2); C(2)-C(1)-C(21)-C(11),$ 80.0(1); $C(12)-C(11)-C(21)-C(1)$, 72.2(1).

methylene carbon $C(21)$ on a line that almost dissects the bond angles $Cl(1)-Pd$ Cl(2), P(1)-Pd-P(2), and C(1)-C(21)-C(11) (*Fig. 3*). In a perfect *C*₂-symmetric arrangement, this line would be the C_2 symmetry axis.

An additional striking feature of the molecular structure of $[PdCl₂((R_n,R_n)-1)]$ is that each of the substituted ferrocenyl cyclopentadienyl (Cp) rings is oriented nearly parallel to one of the phenyl (Ph) rings ($e.g.,$ the Cp ring made of $C(1)$ to $C(5)$ is parallel to the Ph ring consisting of C(34) to C(39), *etc.*) and shows pronounced π -stacking interactions with very short $C \cdots C$ contacts $(e.g., C(1) \cdots C(34) = 3.134,$ $C(5)\cdots C(35)=3.160, C(11)\cdots C(22)=3.115$, and $C(13)\cdots C(27)=3.193$ Å). This stacking interaction certainly contributes a great deal to the stability of the observed C_2 -symmetric conformer. This phenomenon is also present in (R_n, R_n) -1·(BH₃)₂, albeit to a lesser extent (only one $\overline{C} \cdots \overline{C}$ contact < 3.20 Å).

However, although one might expect a C_2 -symmetric or higher-symmetric diphosphine ligand to form a palladium dichloride complex adopting the same symmetry as the free ligand, this is not necessarily the case. For example, in the solid state, the molecular structure of $[PdCl₂(Binap)]$ [24] and also of the related Rh norbornadiene (NBD) complex $[Rh(Binap)(NBD)]ClO₄[25]$ have $C₂$ pseudosymmetry. In contrast, the palladium dichloride complex of bis^{[2-(diphenylphosphino)phenyl]methane, $[PdCl₂(8)]$} [26], with a maximum ligand and complex symmetry of C_{2v} , adopts an asymmetric conformation (*Fig. 4,a*). In solution, average C_2 and C_3 symmetry is observed for [PdCl2(Binap)] and [PdCl2(**8**)], respectively. Since the ligand backbones of **1** and **8**

Fig. 3. *X-Ray crystal structure of* $[PadC_1((R_n, R_n)-1)]$ *CHCl₃. Ellipsoids are shown at the 40% level;* H-atoms have been omitted for clarity. Selected distances ($|\hat{A}|$ and angles $[°]$: Pd-P(1), 2.277(1); Pd-P(2), 2.278(1); Pd-Cl(1), 2.352(1); Pd-Cl(2), 2.362(1); (Fe-C_{Cp)aver}, 2.048(4); P(1)-C(2), $1.798(4)$; P(1)-C(22), $1.813(4)$; P(1)-C(28), $1.838(4)$; P(2)-C(12), $1.812(4)$; P(2)-C(34), $1.810(4)$; $P(2)-C(40)$, 1.814(4); C(21)-C(1), 1.503(5); C(21)-C(11), 1.499(6); C(1)-C(21)-C(11), 117.9(3); $Pd-P(1)-C(2)-C(1), -90.3(4);$ $Pd-P(2)-C(12)-C(11), -87.8(4);$ $P(1)-C(2)-C(1)-C(21),$ $-15.2(6)$; P(2)-C(12)-C(11)-C(21), -7.5(7); C(2)-C(1)-C(21)-C(11), 40.8(6); C(12)-C(11)- $C(21)-C(1), 31.6(7).$

are structurally related to each other (**8** can be obtained from **1** by replacing the ferrocenyl units by aryl rings), we envisaged that, like $[PdCl₂(8)]$, complex $[PdCl₂(1)]$ could adopt *C*1-symmetric conformers. We, therefore, carried out simple force-field calculations (for details see *Exper. Part*) and found that $[PdCl₂(1)]$ can, indeed, adopt not only a C_2 -symmetric conformer (very similar to that found in the solid state), but two homomeric C_1 -symmetric conformers also seem to be accessible [27]. In principle, both *C*1-symmetric conformers are interchangeable by rotation of the ferrocenyl units about the ferrocenyl–CH₂ bonds. Therefore, the observed twofold symmetry of [PdCl₂(1)] in solution could arise either from a C_2 - and/or from two interchanging C_1 -symmetric conformers (*Fig. 4,b*). Since low-temperature ¹H- and ³¹P{¹H}-NMR studies did not show evidence for any exchange phenomena, neither possibility can be excluded (see *Exper. Part*).

Although unexpected, superposition of the molecular structures of complex $[PdCl₂((R_n, R_n)-1)]$, which forms an eight-membered chelate ring system, and complexes $[PdCl₂(*(S)*-Binap)]$ or $[Rh(*(S)*-(Binap))$ (NBD)] $ClO₄$ (with seven-membered chelate rings) shows surprising similarities. The arrangement of the substituted Cp rings is almost identical to that of the naphthyl groups of Binap, placing the P-atoms and, in particular, the attached Ph rings and the transition metal in comparable positions.

Fig. 4. a) *Schematic representation of the molecular structure of* $[PdCl_2(8)]$ *in the solid state. b) Calculated Structures of* C_1 - and C_2 -symmetric conformers of [PdCl₂(1)]

2.3. *Catalysis*. The catalytic behavior of ligand (S_p, S_p) -1 was assessed by screening it in catalytic hydrogenations of the olefins and ketones **9** –**14**. All catalyst precursors were formed *in situ* using an appropriate Rh or Ru source (*Table*). Each hydrogenation reaction gave quantitative or nearly quantitative conversion (*Table*, *Entry 6*), except when methyl 2-oxo-2-phenylacetate (**13**) was used as the substrate. However, the products were formed with only low-to-moderate enantioselectivities. For example, regardless of the Rh source used, hydrogenation of methyl α -(acetamido)cinnamate (9) afforded *N*-acetylphenylalanine methyl ester in 55% enantiomeric purity (*Entries 1* and *2*), and ethyl (*Z*)-3-(acetamido)but-2-enoate (**10**) gave the corresponding butanoate in an enantiomeric excess (ee) of 53% (*Entry 3*). Unfortunately, hydrogenation of the other olefins tested gave products in only very poor enantiomeric purities (17 and 8% ee for **11** (*Entry 4*) and **12** (*Entry 5*), resp.). Similar low ee values were obtained for the Rh- and Ru-mediated hydrogenation of the α - and β -oxo esters 13 and 14 (6 and 15% ee, resp.; *Entries 6* and *7*).

3. Conclusions. – The C_2 -symmetric bis[2-(diphenylphosphino)ferrocenyl]methane ligands (R_n, R_n) - and (S_n, S_n) -1 were synthesized in six steps from (*S*)- and (*R*)-ferrocenyl tolyl sulfoxide, respectively. In the solid state, the complex $[PdCl₂((R_n,R_n)-1)]$ adopts a C_2 -pseudosymmetric conformation, with the chiral pocket being surprisingly similar to those of the Binap complexes $[PdCl_2((S) - Binap)]$ and $[Rh((S) - (Binap))(NBD)]ClO₄$. However, when diphosphine **1** was used as the ligand in Rh- and Ru-catalyzed hydrogenations of olefins and ketones, only low-to-moderate enantioselectivities were obtained. Based on the X-ray crystal structure of $[PolCl₂(8)]$ (8=bis[2-(diphenylphos-

Table. *Rhodium-and Ruthenium-Catalyzed Hydrogenations of Alkenes and Ketones in the Presence of the New Ligand* (S_p , S_p)-**1**

^a) $A: \text{MeOH (10 ml)}$; substrate/catalyst (S/C): 200 :1, 25°. $B: \text{EtOH (10 ml)}$, S/C 100 :1, 25°. *C*: Toluene (10 ml) , S/C 200 : 1, 25°. *D*: EtOH (10 ml), S/C 200 : 1, 25°. b) Determined by GC (*Chirasil-L-Val*, 170°, isothermal). ^c) By GC (*Lipodex E*, 130°, isothermal). ^d) By HPLC (*Chiralcel OB*, hexane/i-PrOH 98:2, 0.1 ml/min) of Me ester. ^e) By GC (*Lipodex E*, 80°, isothermal). ^f) By HPLC (*Chiralcel OJ*, hexane/i-PrOH 90:10, 1.0 ml/min). ^g) By GC (*Lipodex E*, 80 $^{\circ}$, isothermal) of TFA derivative.

phino)phenyl]methane) and corroborated by simple force-field calculations on $[PdCl₂(1)]$, we assume that, unlike in the case of Binap in solution, transition-metal complexes of ligand 1 are much more flexible and are not only able to adopt C_2 - but also C_1 -symmetric conformations, an observation that could well be responsible for the low enantioselectivities observed.

This work was supported by *Solvias AG* (Basel) and by the *Österreichischer Akademischer Austauschdienst*.

Experimental Part

General. All manipulations were carried out under Ar atmosphere using standard *Schlenk* techniques. Solvents were distilled from the appropriate drying agents, and degassed before use. Chromatographic separations were performed under gravity, either on silica gel (40–62 mm; *Merck*) or on alumina (activity II–III, $63-200$ um; *Merck*). Petroleum ether (PE) with a boiling range of $55-65^{\circ}$ was used for column chromatography (CC). (S_c) -(4-Methylphenyl)sulfinylferrocene ((S_c) -2) and 2 -[(4-methylphenyl)*sulfinyl]-1-(tributylstannyl)ferrocene* ((S_c , R_p)-4) were prepared according to [21]. Melting points (m.p.) were determined on a *Kofler* melting-point apparatus; uncorrected. Optical rotations were measured on a *Perkin Elmer 241* polarimeter. NMR Spectra were recorded on a *Bruker DPX-400* spectrometer

in CDCl₃; chemical shifts δ in ppm rel. to CHCl₃ (¹H: 7.26 ppm), CDCl₃ (¹³C{¹H}: 77.0 ppm), or 85% H_3PO_4 (${}^{31}P({}^{1}H)$: 0 ppm); coupling constants *J* in Hz; in the ${}^{13}C$ -NMR spectra, the *J* values refer to 13C,31P couplings. Abbreviations: br., *s*, *d*, *t*, and *q* refer to broad, *singlet*, *doublet*, *triplet*, and *quartet*, resp., and C_q (¹³C-NMR) stands for quaternary C-atom; for arbitrary atom numbering, see *Fig.* 2. Low-temp. NMR spectra of $[PdCl₂(1)]$ were recorded on a *Bruker Avance-300* spectrometer in CD₂Cl₂ in a temp. range of -80 to $+25^{\circ}$. Mass spectra were recorded on a *Finnigan MAT-8230* apparatus (EI) or on *Finnigan MAT-900S* (FD); in *m*/*z*. Elemental analyses were performed by the Mikroanalytisches Laboratorium der Fakultät für Chemie der Universität Wien.

2-(Tributylstannyl)ferrocene-1-carbaldehyde ((R_p)-5). To a degassed soln. of (S_c,R_p)-4 (9 g, 14.6 mmol) in THF (80 ml) at -78° under Ar gas was added dropwise 1.7*M t*-BuLi in pentane (9.46 ml, 16.09 mmol) *via* syringe. The soln. was stirred at -78° for 5 min. Then, DMF (3.41 ml, 43.89 mmol) was added, and the soln. was stirred for an additional 2 h at -78° . Then, the reaction was quenched with H₂O (20 ml). The product was extracted with Et₂O, the org. phase was washed with H₂O and brine, dried (MgSO₄), and concentrated under reduced pressure. The residue was purified by CC (*Alox 90*; PE/Et₂O 9:1) to afford (R_n) -**5** (6.42 g) in 87% yield. The spectroscopic and physical data were identical with those reported in [22]. Red oil. ¹H-NMR (400 MHz): 0.91 (*t*, $J=7.3$, 3 Me); 1.01–1.15 (*m*, 3 CH2); 1.30–1.42 (*m*, 3 CH2); 1.47–1.62 (*m*, 3 CH2); 4.22 (*s*, 5 H of Cp'); 4.45–4.51 (*m*, 1 H of Cp); 4.74 (*t*, *J*=2.4, 1 H of Cp); 4.90–4.94 (*m*, 1 H of Cp); 9.94 (*s*, HCO).

*(*Rp,Rp*)-Bis[(2-(tributylstannyl)ferrocen-1-yl]methanol* (*Rp*,*Rp*)-**6**. To a degassed soln. of (*Sc*,*Rp*)-**4** (7.85 g, 12.76 mmol) in THF (80 ml) at -78° under Ar gas was added dropwise 1.7*M t*-BuLi in pentane (8.26 ml, 14.04 mmol) *via* syringe, and the soln. was stirred at -78° for 5 min. A degassed soln. of (R_p) **-5** $(6.42 \text{ g}, 12.76 \text{ mmol})$ in THF (5 ml) was added, and the mixture was stirred for another 2 h at -78° . Then, the mixture was allowed to reach r.t., and the reaction was quenched with $H₂O$ (20 ml). The product was extracted with Et₂O, the org. phase was washed with H₂O and brine, dried (MgSO₄), and concentrated under reduced pressure. The residue was purified by CC (*Alox 90*; PE/Et₂O 100 :1) to afford (R_mR_p)-6 (9.94 g) in 80% yield. Due to its rather low stability, the compound was immediately used in the next step. Orange oil. ¹ H-NMR (400 MHz): 0.85–0.98 (*m*, 6 Me); 1.00–1.14 (*m*, 6 CH2); 1.32–1.45 (*m*, 6 CH2); 1.49–1.66 (*m*, 6 CH2); 2.28 (*d*, *J*=2.4, OH); 3.93–3.96 (*m*, 1 H of Cp); 3.97–4.00 (*m*, 1 H of Cp); 4.12 (*s*, 5 H of Cp'); 4.15–4.17 (*m*, 1 H of Cp); 4.18 (*s*, 5 H of Cp'); 4.22 (*t*, *J*=2.3, 1 H of Cp); 4.28 (*t*, *J*=2.4, 1 H of Cp); 4.32–4.36 (*m*, 1 H of Cp); 5.08 (*d*, *J*=2.4, 1 CH). 13C{1 H}-NMR (100.6 MHz): 10.92 (CH₂); 11.59 (CH₂); 13.72 (Me); 13.77 (Me); 27.53 (CH₂); 27.62 (CH₂); 29.34 (CH₂); 29.47 (CH₂); 66.92 (C_q of Cp); 67.82 (CH); 68.26 (Cp'); 68.59 (Cp'); 69.40 (CH); 69.51 (C_q of Cp); 69.66 (CH); 70.13 (CH); 70.75 (CH); 74.19 (CH); 74.24 (CH); 97.44 (C_q of Cp); 102.21 (C_q of Cp). FD-MS: 978.0 (*M*⁺).

 (R_p, R_p) -Bis[2-(tributylstannyl)ferrocen-1-yl]methane $((R_p, R_p)$ -7). To a degassed soln. of (R_p, R_p) -6 $(5 g, 5.11 mmol)$ in THF (40 ml) was added dropwise 1M BH₃ in THF (40.88 ml, 40.88 mmol). The mixture was heated at reflux for 7 h, until the starting material was consumed according to TLC analysis (alumina; PE). The mixture was cooled to 0° , quenched by addition of H₂O, extracted with Et₂O, washed with H2O and brine, dried (MgSO4), and concentrated under reduced pressure. The residue was purified by CC (*Alox 90*; PE/Et₂O 100:1) to afford (R_p, R_p) -7 (3.82 g) in 78% yield. Orange oil. $[a]_{{\lambda}}^{20}$ (λ in nm): 17.4 (589), 20.0 (578), 36.9 (546) (*c*=0.88, CHCl3). ¹ H-NMR (400.1 MHz): 0.97 (*t*, *J*=7.33, 6 Me); 1.05–1.24 (*m*, 6 CH2); 1.37–1.48 (*m*, 6 CH2), 1.55–1.70 (*m*, 6 CH2); 3.38 (*s*, 1 CH2); 3.83 (*dd*, *J*=2.3, 1.3, 2 H of Cp, exchangeable); 4.06 (*s*, 2× 5 H of Cp'); 4.13–4.16 (*m*, 2 H of Cp, exchangeable); 4.17 (*t*, *J* = 2.3, 2 H of Cp). ¹³C{¹H}-NMR (100.6 MHz): 10.85 (CH₂); 13.72 (Me); 27.57 (CH₂); 29.40 $(CH₂)$; 33.38 (CH₂); 68.60 (Cp'); 69.57 (C_q of Cp); 70.34 (C(4) of Cp); 70.38 (C(5) of Cp); 73.82 (C(3) of Cp); 94.75 (Cq of Cp). FD-MS: 962 (*M*⁺).

*(m-{(*Rp,Rp*)-Bis[2-(diphenylphosphino)ferrocen-1-yl]methane-*P*,*P*})hexahydrodiboron* ((*Rp*,*Rp*)-**1**· $(HH₃)₂$). To a degassed soln. of (R_p, R_p) -**7** (2.5 g, 2.6 mmol) in THF (20 ml) at 0° under Ar gas was added dropwise 1.6M BuLi (in hexane; 3.41 ml, 5.46 mmol) *via* syringe. The soln. was stirred at this. temp. for 10 min, and Ph₂PCl (1.4 ml, 7.8 mmol) was added. The mixture was stirred for a further 30 min at 0° , and then allowed to reach r.t. Stirring was continued, until all starting material was consumed (TLC control (alumina; $PE/Et₂O 10:1$)). Then, 1M BH₃ in THF (20.8 ml, 20.8 mmol) was added, and the mixture was stirred for a further 16 h at r.t. The mixture was quenched with sat. aq. NaHCO₃ soln.,

extracted with Et₂O, washed with H₂O and brine, dried (MgSO₄), and concentrated under reduced pressure. The residue was purified by CC (*Alox 90*; PE/Et, O/Et₃N 10:4:0.1) to afford ($R_{\mu}R_{\mu}$)-**1** (0.64 g) in 32% yield. Yellow solid. M.p. > 243° (dec.). $[a]_2^{20}$ (λ in nm): +129.0 (589), +128.4 (578), +103.2 (546) (*c*=0.98, CHCl3). ¹ H-NMR (400.1 MHz): 1.24–2.18 (very br. *s*, 2 BH3); 3.42–3.46 (*m*, 2 H of Cp); 3.71 (*t*, *J*=2.5, 2 H of Cp); 3.90–3.93 (*m*, 2 H of Cp); 4.13 (*s*, 2× 5 H of Cp'); 4.14 (*s*, 1 CH2); 7.31–7.38 (*m*, 4 H of Ph); 7.39–7.52 (*m*, 12 H of Ph); 7.60–7.72 (*m*, 4 H of Ph). 13C{1 H}-NMR (100.6 MHz): 26.93 (CH2); 67.42 (*d*, *J*=65.0, Cq of Cp); 69.54 (*d*, *J*=6.1, C(4) of Cp); 70.49 (Cp'); 72.37 (*d*, *J*=3.8, C(3) of Cp); 74.27 (*d*, *J*=7.6, C(5) of Cp); 92.86 (*d*, *J*=15.7, Cq of Cp); 128.08, 128.15, 128.18, 128.25 (*2d*, 4 *m*-C of Ph); 130.68 (*d*, *J*=2.3, 2 *p*-C of Ph); 130.85 (*d*, *J*=2.3, 2 *p*-C of Ph); 131.29, 131.48, 132.04 (4 *ipso*-C of Ph); 132.99 (*d*, *J*=9.2, 2 *o*-C of Ph); 133.32 (*d*, *J*=9.2, 2 *o*-C of Ph). 31P{1 H}-NMR (162.0 MHz): 15.68 (br. *s*). EI-MS (270°): 780 (1, *M*⁺), 766 (9, [*M*-BH₃]⁺), 752 (100, [*M*-2 BH₃]⁺), 566 (96), 500 (18), 445 (16).

 (R_p, R_p) -Bis[2-(diphenylphosphino)ferrocen-1-yl]methane $((R_p, R_p)$ -1). A soln. of (R_p, R_p) -1·(BH₃)₂ $(1.14 \text{ g}, 1.46 \text{ mmol})$ in freshly distilled Et.NH (20 ml) was stirred for 4 h at r.t., until the starting material was consumed (TLC). The solvent was removed under reduced pressure, and the residue was purified by CC (*Alox 90*; PE/Et₂O/Et₃N 70:30:3) to afford (R_mR_p) -1 (1.07 g) in 98% yield. Yellow solid. M.p. 154–158°. $[a]_2^{20}$ (λ in nm): +267.7 (589), +278.4 (578), +318.8 (546) (c =0.96, CHCl₃). ¹H-NMR (400.1 MHz): 3.46–3.52 (*m*, 2 H of Cp, exchangeable); 3.70 (*t*, *J*=2.4, 2 H of Cp); 3.88 (*s*, 2×5 H of Cp'); 3.90 (*s*, 1 CH2); 3.92–3.95 (*m*, 2 H of Cp, exchangeable); 7.03–7.12 (*m*, 4 H of Ph); 7.16–7.23 (*m*, 6 H of Ph); 7.32–7.40 (*m*, 6 H of Ph); 7.49–7.59 (*m*, 4 H of Ph). 13C{1 H}-NMR (100.6 MHz): 28.83 (*t*, *J*=9.1, CH2); 68.59 (C(4) of Cp); 69.53 (Cp'); 70.48 (*d*, *J*=3.8, C(3) of Cp); 73.03 (*t*, *J*=4.6, C(5) of Cp); 74.38 (*d*, *J*=6.1, Cq of Cp); 93.55 (*d*, *J*=27.1, Cq of Cp); 127.60 (2 *p*-C of Ph); 127.69 (*d*, *J*=6.1, 4 *m*-C of Ph); 127.99 (*d*, *J*=8.4, 4 *m*-C of Ph); 128.98 (2 *p*-C of Ph); 132.64 (*d*, *J*=17.59, *o*-C of Ph); 135.19 (*d*, *J*=20.6, *o*-C of Ph); 137.68 (*d*, *J*=6.9, 2 *ipso*-C of Ph); 140.10 (*d*, *J*=8.4, 2 *ipso*-C of Ph). ³¹P{¹H}-NMR (162.0 MHz): -22.55 (*s*). EI-MS (230°): 752 (67, *M*⁺), 566 (100), 500 (12), 424 (13). Anal. calc. for C₄₅H₃₈Fe₂P₂: C 71.83, H 5.09, P 8.23, found: C 71.95, H 5.44, P 8.06.

*Dichloro(m-{(*Rp,Rp*)-bis[2-(diphenylphosphino)ferrocen-1-yl]methane-P,P})palladium(II)* ([PdCl2- $((R_m, R_p)$ -**1**)]. A degassed soln. of (R_m, R_p) -**1** (75 mg, 0.1 mmol) in benzene (2 ml) was added to a suspension of $[PdCl₂(MeCN)₂]$ (24 mg, 0.094 mmol) in benzene (2 ml) through a *Teflon* tube. The mixture was stirred for 18 h at r.t., and the resulting precipitate was filtered off and washed with both benzene (2×2) ml) and Et₂O (3×3 ml) to afford the title compound (81 mg) in 87% yield. Red solid. M.p. > 215° (dec.). $[a]_D^{20} = -838$ (*c*=0.06, CHCl₃). ¹H-NMR (400.1 MHz): 3.64–3.67 (*m*, 2 H of Cp); 3.68–3.71 (*m*, 2 H of Cp); 3.77 (*s*, 2× 5 H of Cp'); 3.91 (*s*, 1 CH2); 3.96–4.01 (*m*, 2 H of Cp); 7.27–7.33 (*m*, 4 *m*-H of Ph1); 7.33–7.40 (*m*, 2 *p*-H of Ph1); 7.41–7.49 (*m*, 4 *m*-H of Ph2); 7.50–7.56 (*m*, 2 *p*-H of Ph2); 7.56–7.66 (*m*, 4 *o*-H of Ph¹); 8.51–8.62 (*m*, 4 *o*-H of Ph²); the Ph² H-atoms are stacking to the Cp ring. ¹³C{¹H}-NMR (100.6 MHz): 31.96 (CH2); 69.83 (br*. s*, C(4) of Cp); 70.66 (Cp'); 73.08 (*d*, *J*=16.1, C(3) of Cp); 75.03 (br. *s*, C(5) of Cp); 126.61 (*d*, *J*=12.2, 4 *m*-C of Ph1); 128.42 (*d*, *J*=11.5, 4 *m*-C of Ph²); 130.34 (2 *p*-C of Ph); 131.81 (2 *p*-C of Ph); 134.36 (*d*, *J*=11.8, *o*-C of Ph1); 135.90 (*d*, *J*=13.0, *o*-C of Ph2); the C_q- and *ipso*-C-atoms of the Ph rings were not observed. ³¹P{¹H}-NMR (162.0 MHz): 31.60 (*s*).

 \overline{X} -Ray Crystal-Structure Determination¹) of (R_p, R_p) -1· $(BH_3)_2$ and $[PdCl_2((R_p, R_p)$ -1)]·*CHCl₃.* Crystals of (R_p, R_p) **-1**· (BH₃)₂ were obtained by layering a CH₂Cl₂ soln. with Et₂O, and crystals of [PdCl₂((R_p , R_p)-**1**)]· CHCl₃ were obtained by evaporation of a CHCl₃ soln. of the target compound. X-ray data were collected on a *Bruker Smart CCD* area-detector diffractometer using graphite-monochromated Mo*K^a* radiation (λ =0.71073 Å), with 0.3° ω -scan frames covering the complete spheres of the reciprocal space. After frame data integration with the SAINT program [28], corrections were applied for absorption, *l*/2 effects, and crystal decay using the SADABS program [28]. The structures were solved by direct

¹) CCDC 299604-299606 contain the supplementary crystallographic data for this paper. These data can be obtained, free of charge, from the *Cambridge Crystallographic Data Centre* at www.ccdc.cam. ac.uk/data_request/cif. Note that the data includes the room-temperature structure of $[PdCl_2((R_p,R_p)-1)] \cdot CH_3NO_2$, a nitromethane solvate that is isostructural with $[PdCl_2((R_p,R_p)-1)] \cdot$ CHCl₃.

methods using the program SHELXS97 [29]. Structure refinement on *F2* was carried out with the program SHELXL97 [29]. All non-H-atoms were refined anisotropically. H-Atoms were inserted in idealized positions, and were refined riding with the atoms to which they are bonded. Views of the molecular structures are shown in *Figs. 2* and *3*, and selected geometric data are given in the figure legends.

Crystal data for (R_p, R_p) -**1**· (BH₃)₂. Formula, C₄₅H₄₄B₂Fe₂P₂; *M_r* 780.06; *T*=100(2) K; orthorhombic, space group *P*212121 (No. 19); *a*=12.2672(14), *b*=13.9364(16), *c*=22.063(3) Å; *V*=3771.8(8) Å3 ; *Z*=4; μ =0.89 mm⁻¹. Of 55,054 reflections collected (θ_{max} =30°), 10,961 were independent; final *R* indices: R_1 = 0.0209 (all data), wR_2 = 0.0529 (all data); *Flack* absolute structure parameter = $-$ 0.008(5).

Crystal data for $[PdCl_2((R_p, R_p)-1)]$ ·CHCl₃. Formula, $C_{46}H_{39}Cl_5Fe_2P_2Pd$, M_r 1049.06; $T=100(2)$ K; tetragonal, space group *P*43212 (No. 96); *a*=14.2830(12), *c*=40.512(4) Å; *V*=8264.7(12) Å3 ; *Z*=8; μ = 1.56 mm⁻¹. Of 109,989 reflections collected (θ_{max} = 28.3°), 10,160 were independent; final *R* indices: $R_1 = 0.0449$ (all data), $wR_2 = 0.0903$ (all data); *Flack* absolute structure parameter = -0.011(18).

Standard Procedure for Hydrogenation Reactions. The substrate (2.53 mmol) and the catalyst (formed *in situ*, for details see *Table*) were dissolved separately in 5 ml of the solvent under Ar gas (total volume: 10 ml). The catalyst soln. was stirred for 15 min. Both the catalyst and the substrate soln. were then transferred through a steel capillary either into a 180-ml thermostated glass reactor or into a 50-ml stainless-steel autoclave. The inert gas was then replaced by $H₂$ (three cycles), and the pressure was set. After completion of the reaction $(1–20 h)$ according to GC analysis), the product was isolated quantitatively after filtration through a plug of $SiO₂$ to remove the catalyst. The enantiomeric purity of the product was determined either by GC or HPLC (see *Table*).

Force-Field Calculations. Computer modeling was carried out with the program PCMODEL (vers. 8.50.0) [27] and *Allinger*'s MMX force field. The minimization 'Steepest Descent' followed by *Newton–Raphson* were applied in each case. A square-planar Pd coordination sphere was predefined. All conformers of $[PdCl₂(1)]$ were minimized in two different ways: by including PI calculations as well as by using a predefined atom type (atom type 40) for all aromatic C-atoms. With both methods, the *C*1-symmetric conformer was calculated to be more stable than the C_2 -symmetric one (3.2 (PI) *vs.* 4.9 kcal/mol, resp.).

REFERENCES

- [1] T. Ohkuma, M. Kitamura, R. Noyori, in 'Catalytic Asymmetric Synthesis', Ed. I. Ojima, Wiley-VCH, Weinheim, 2000, p. 1; H. Brunner, in 'Applied Homogeneous Catalysis with Organometallic Compounds', Eds. B. Cornils, W. A. Herrmann, VCH, Weinheim, 1996, p. 201; R. Noyori, 'Asymmetric Catalysis in Organic Synthesis', Wiley, 1993, p. 16.
- [2] 'Asymmetric Catalysis on Industrial Scale: Challenges, Approaches and Solutions', Eds. H. U. Blaser, E. Schmidt, Wiley-VCH, Weinheim, 2004; H. U. Blaser, B. Pugin, F. Spindler, *J. Mol. Catal. A* **2005**, *231*, 1; H. U. Blaser, M. Studer, F. Spindler, *Appl. Catal.*, *A* **2001**, *221*, 119.
- [3] J. M. Brown, in 'Comprehensive Asymmetric Catalysis', Eds. E. N. Jacobsen, A. Pfaltz, H. Yamamoto, Springer, 1999, Vols. I–III, p. 21; T. Ohkuma, R. Noyori, in 'Comprehensive Asymmetric Catalysis', Eds. E. N. Jacobsen, A. Pfaltz, H. Yamamoto, Springer, 1999, Vols. I–III, p. 199.
- [4] W. S. Knowles, in 'Asymmetric Catalysis on Industrial Scale', Eds. H. U. Blaser, E. Schmidt, Wiley-VCH, Weinheim, 2004, p. 23; W. S. Knowles, M. J. Sabacky, B. D. Vineyard, D. J. Weinkauff, *J. Am. Chem. Soc.* **1975**, *97*, 2567.
- [5] R. Noyori, 'Asymmetric Catalysis in Organic Synthesis', Wiley, 1993; A. Miyashita, A. Yasuda, H. Takaya, K. Toriumi, T. Ito, T. Souchi, R. Noyori, *J. Am. Chem. Soc.* **1980**, *102*, 7932.
- [6] C. J. Cobley, B. N. Johnson, I. C. Lennon, R. McCague, J. A. Ramsden, A. Zanotti-Gerosa, in 'Asymmetric Catalysis on Industrial Scale', Eds. H. U. Blaser, E. Schmidt, Wiley-VCH, Weinheim, 2004, p. 269; M. J. Burk, *J. Am. Chem. Soc.* **1991**, *113*, 8518.
- [7] H. U. Blaser, W. Brieden, B. Pugin, F. Spindler, M. Studer, A. Togni, *Top. Catal.* **2002**, *19*, 3.
- [8] T. P. Dang, H. P. Kagan, *Chem. Commun.* **1971**, 481.
- [9] T. Jerphagnon, J. L. Renaud, C. Bruneau, *Tetrahedron: Asymmetry* **2004**, *15*, 2101; C. Claver, E. Fernandez, A. Gillon, K. Heslop, D. J. Hyett, A. Martorell, A. G. Orpen, P. G. Pringle, *Chem. Commun.* **2000**, 961; M. T. Reetz, G. Mehler, *Angew. Chem., Int. Ed.* **2000**, *39*, 3889; M. van den Berg, A. J.

Minnaard, E. D. Schudde, J. van Esch, A. H. M. de Vries, B. L. Feringa, *J. Am. Chem. Soc.* **2000**, *122*, 11539.

- [10] P. Barbaro, C. Bianchini, G. Giambastiani, S. L. Parisel, *Coord. Chem. Rev.* **2004**, *248*, 2131; R. C. J. Atkinson, V. C. Gibson, N. J. Long, *Chem. Soc. Rev.* **2004**, *33*, 313; T. J. Colacot, *Chem. Rev*. **2003**, *103*, 3101; 'Ferrocenes: Homogeneous Catalysis, Organic Synthesis, Materials Science', Eds. A. Togni, T. Hayashi, VCH, Weinheim, 1995.
- [11] T. Sturm, W. Weissensteiner, F. Spindler, K. Mereiter, A. M. López-Agenjo, B. R. Manzano, F. A. Jalón, *Organometallics* **2002**, *21*, 1766.
- [12] L. Xiao, K. Mereiter, F. Spindler, W. Weissensteiner, *Tetrahedron: Asymmetry* **2001**, *12*, 1105.
- [13] T. Sturm, W. Weissensteiner, F. Spindler, *Adv. Synth. Catal.* **2003**, *345*, 160.
- [14] U. Nettekoven, M. Widhalm, P. C. J. Kamer, P. W. N. M. van Leeuwen, *Tetrahedron: Asymmetry* **1997**, *8*, 3185; F. Maienza, M. Wörle, P. Steffanut, A. Mezzetti, F. Spindler, *Organometallics* **1999**, *18*, 1041.
- [15] L. Schwink, P. Knochel, *Chem.–Eur. J.* **1998**, *4*, 950; T. Hayashi, A. Yamamoto, M. Hojo, Y. Ito, *J. Chem. Soc., Chem. Commun*. **1989**, 495.
- [16] M. Sawamura, A. Yamauchi, T. Takegawa, Y. Ito, *J. Chem. Soc., Chem. Commun*. **1991**, 874.
- [17] M. Sawamura, H. Hamashima, Y. Ito, *Tetrahedron: Asymmetry* **1991**, *2*, 593.
- [18] S. L. You, X. L. Hou, L. X. Dai, B. X. Cao, J. Sun, *Chem. Commun.* **2000**, 1933.
- [19] R. G. Arrayás, I. Alonso, O. Familiar, J. C. Carretero, *Organometallics* **2004**, *23*, 1991.
- [20] F. Rebière, O. Riant, L. Ricard, H. B. Kagan, *Angew. Chem., Int. Ed.* **1993**, *32*, 568.
- [21] O. Riant, G. Argouarch, D. Guillaneux, O. Samuel, H. B. Kagan, *J. Org. Chem.* **1998**, *63*, 3511.
- [22] O. Riant, O. Samuel, T. Flessner, S. Taudien, H. B. Kagan, *J. Org. Chem.* **1997**, *62*, 6733; A. Brunner, S. Taudien, O. Riant, H. B. Kagan, *Chirality* **1997**, *9*, 478; O. Riant, O. Odile, H. B. Kagan, *J. Am. Chem. Soc.* **1993**, *115*, 5835.
- [23] L. Routaboul, J. Chiffre, G. G. A. Balavoine, J. C. Daran, E. Manoury, *J. Organomet. Chem*. **2001**, *637 – 639*, 364.
- [24] F. Ozawa, A. Kubo, Y. Matsumoto, T. Hayashi, E. Nishioka, K. Yanagi, K. Moriguchi, *Organometallics* **1993**, *12*, 4188.
- [25] K. Toriumi, T. Ito, H. Takaya, T. Souchi, R. Noyori, *Acta Crystallogr., Sect. B* **1982**, *38*, 807.
- [26] W. Lesueur, E. Solari, C. Floriani, A. Chiesi-Villa, C. Rizzoli, *Inorg.Chem.* **1997**, *36*, 3354.
- [27] PCMODEL, vers. 8.50.0, *Serena Software*, Bloomington, IN, U.S.A.
- [28] *Bruker* Software SMART (vers. 5.625), SAINT (vers. 6.22), SADABS (vers. 2.10), XPREP (vers. 6.12), SHELXTL (vers. 6.12), *Bruker AXS, Inc.*, Madison, WI, U.S.A., 2001.
- [29] G. M. Sheldrick, SHELX97, Program System for Crystal Structure Determination, University of Göttingen, Germany, 1997.

Received March 29, 2006